2021
Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer’s disease subgroups
Groot C, Grothe MJ, Mukherjee S, Jelistratova I, Jansen I, van Loenhoud AC, Risacher SL, Saykin AJ, Mac Donald C, Mez J, Trittschuh EH, Gryglewski G, Lanzenberger R, Pijnenburg YAL, Barkhof F, Scheltens P, van der Flier WM, Crane PK, Ossenkoppele R. Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer’s disease subgroups. NeuroImage Clinical 2021, 30: 102660. PMID: 33895633, PMCID: PMC8186562, DOI: 10.1016/j.nicl.2021.102660.Peer-Reviewed Original ResearchConceptsGray matter volumeRegional GM volumeAd memoryAd executivesGM volumeMatter volumeRegional gray matter volumeVoxel-wise contrastsAlzheimer’s disease subgroupsCognitive domainsCognitive profileNeuropsychological assessmentNeurobiological mechanismsNeurobiological differencesPsychometric frameworkAd languageRelative impairmentTemporal lobeHuman brainAllen Human Brain AtlasDifferential patternsStructural MRILower GM volumeHuman Brain AtlasPosterior areas
2019
Changes in White Matter Microstructure After Electroconvulsive Therapy for Treatment-Resistant Depression
Gryglewski G, Seiger R, Baldinger-Melich P, Unterholzner J, Spurny B, Vanicek T, Hahn A, Kasper S, Frey R, Lanzenberger R. Changes in White Matter Microstructure After Electroconvulsive Therapy for Treatment-Resistant Depression. The International Journal Of Neuropsychopharmacology 2019, 23: 20-25. PMID: 31740958, PMCID: PMC7064047, DOI: 10.1093/ijnp/pyz059.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionElectroconvulsive therapyWhite matter microstructureRight unilateral electroconvulsive therapyDiffusivity metricsUnipolar treatment-resistant depressionPoor antidepressant responseEffective therapeutic optionUnilateral electroconvulsive therapyDiffusion tensor imaging sequencesElectrode placementTract-based spatial statisticsAntidepressant responseClinical outcomesTherapeutic optionsInternal capsuleRepeated-measures ANOVAPosterior limbTreatment responseMagnetic resonanceElectrical stimulationTherapyAxial diffusivityLeft hemisphereWarrants investigationHippocampal Subfields in Acute and Remitted Depression—an Ultra-High Field Magnetic Resonance Imaging Study
Kraus C, Seiger R, Pfabigan D, Sladky R, Tik M, Paul K, Woletz M, Gryglewski G, Vanicek T, Komorowski A, Kasper S, Lamm C, Windischberger C, Lanzenberger R. Hippocampal Subfields in Acute and Remitted Depression—an Ultra-High Field Magnetic Resonance Imaging Study. The International Journal Of Neuropsychopharmacology 2019, 22: 513-522. PMID: 31175352, PMCID: PMC6672627, DOI: 10.1093/ijnp/pyz030.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAntidepressive Agents, Second-GenerationAustriaCitalopramDepressive Disorder, MajorDrug SubstitutionFemaleHippocampusHumansMagnetic Resonance ImagingMaleMiddle AgedPredictive Value of TestsRemission InductionSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsTreatment OutcomeVenlafaxine HydrochlorideYoung AdultConceptsMajor depressive disorderDepressive disorderHippocampal subfieldsSubfield volumesAntidepressant treatmentHealthy controlsHippocampal-amygdaloid transition areaMajor depressive disorder patientsOpen-label studyMagnetic resonance imaging studyDepressive disorder patientsHippocampal formation volumeStructural magnetic resonance imagingHippocampal volume changesLower baseline volumesTreatment-related changesResonance imaging studyMagnetic resonance imagingMeasurement time pointsSerotonergic antidepressantsWeeks treatmentAcute patientsRight subiculumUnmedicated patientsBaseline volumeModeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging
Gryglewski G, Klöbl M, Berroterán-Infante N, Rischka L, Balber T, Vanicek T, Pichler V, Kautzky A, Klebermass EM, Reed MB, Vraka C, Hienert M, James GM, Silberbauer L, Godbersen GM, Unterholzner J, Michenthaler P, Hartenbach M, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hahn A, Hacker M, Kasper S, Lanzenberger R. Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. European Neuropsychopharmacology 2019, 29: 711-719. PMID: 31076187, DOI: 10.1016/j.euroneuro.2019.04.001.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsReuptake inhibitorsPharmacological responsePharmacological imagingFunctional MRIRandomized double-blind designResting-state functional MRIAcute pharmacological responsesCitalopram plasma concentrationsPrevalent neuropsychiatric conditionsDouble-blind designMechanism of actionPlacebo scansInfusion paradigmPlasma levelsSSRI effectsDrug challengePatient outcomesPlasma concentrationsDrug infusionInfluence treatmentConstant infusionLarger sample sizePET/MR scansEpistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression
Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Hartmann AM, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. Translational Psychiatry 2019, 9: 5. PMID: 30664620, PMCID: PMC6341100, DOI: 10.1038/s41398-018-0308-2.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factor (BDNF) geneAffective disordersReceptor bindingSingle nucleotide polymorphismsPhenotype of depressionNeurotrophic factor geneSerotonin 1A receptor geneFunctional single nucleotide polymorphismsReceptor profileHealthy subjectsPET resultsRisk genotypesRs6265Multifactorial riskCortical regionsMixed modelsRisk allelesRs6295DisordersCortical surfaceReceptor geneReceptorsMolecular phenotypesHTR1ADepressionThe effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography
Baldinger-Melich P, Gryglewski G, Philippe C, James GM, Vraka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz GS, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimulation 2019, 12: 714-723. PMID: 30635228, DOI: 10.1016/j.brs.2018.12.976.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyTRD patientsMAO-A levelsHealthy subjectsPositron emission tomographyTest-retest variabilityMechanism of actionEffective antidepressant treatment strategiesSex-matched healthy subjectsEmission tomographyAntidepressant treatment strategiesMonoamine oxidaseTreatment-resistant depressionTreatment-resistant patientsSerotonin 1A receptorUnmedicated depressed patientsCerebral monoamine oxidasesCerebral MAOAntidepressant pharmacotherapyECT sessionsAntidepressant treatmentDepressed patientsMajor depressionSerotonergic systemTreatment strategies
2018
Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis
Gryglewski G, Baldinger-Melich P, Seiger R, Godbersen GM, Michenthaler P, Klöbl M, Spurny B, Kautzky A, Vanicek T, Kasper S, Frey R, Lanzenberger R. Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis. The British Journal Of Psychiatry 2018, 214: 159-167. PMID: 30442205, PMCID: PMC6383756, DOI: 10.1192/bjp.2018.224.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionElectroconvulsive therapyMagnetic resonance imagingCortical thicknessHippocampal subfieldsAmygdala nucleiHippocampal-amygdaloid transition areaRight unilateral electroconvulsive therapyEffects of ECTHigh-resolution structural magnetic resonance imagingUnipolar treatment-resistant depressionCorticoamygdaloid transition areaPathophysiology of depressionPre-post study designCorrelation of imagingUnilateral electroconvulsive therapyTreatment of choiceStructural magnetic resonance imagingSpecific hippocampal subfieldsSevere mental illnessGrant/research supportStress-related disordersClinical parametersRepeated-measures ANOVADentate gyrusParcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo
James GM, Gryglewski G, Vanicek T, Berroterán-Infante N, Philippe C, Kautzky A, Nics L, Vraka C, Godbersen GM, Unterholzner J, Sigurdardottir HL, Spies M, Seiger R, Kranz GS, Hahn A, Mitterhauser M, Wadsak W, Bauer A, Hacker M, Kasper S, Lanzenberger R. Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. Cerebral Cortex 2018, 29: 372-382. PMID: 30357321, PMCID: PMC6294402, DOI: 10.1093/cercor/bhy249.Peer-Reviewed Original ResearchConceptsPositron emission tomographyEmission tomographySerotonin neurotransmitter systemSerotonin 1ACerebral cortexEnzyme monoamine oxidase AMonoamine oxidase ANeurotransmitter systemsSerotonin systemPsychotropic drugsNeuropsychiatric disordersBrain functionHealthy participantsSerotonin transporterMolecular imaging dataMolecular targetsMolecular profileOxidase AWhole-brain coverageCortexParcellationTomographyDefined clustersClose associationImaging data
2017
The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning
Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning. Translational Psychiatry 2017, 7: e1150-e1150. PMID: 28608854, PMCID: PMC5537636, DOI: 10.1038/tp.2017.108.Peer-Reviewed Original Research
2015
Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding
Baldinger P, Kraus C, Rami-Mark C, Gryglewski G, Kranz GS, Haeusler D, Hahn A, Spies M, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. NeuroImage 2015, 111: 505-512. PMID: 25652393, DOI: 10.1016/j.neuroimage.2015.01.049.Peer-Reviewed Original ResearchConceptsPositron emission tomographySerotonin transporterSerotonin releaseRespective projection areasReuptake of serotoninExtracellular serotonin concentrationBilateral parahippocampal gyrusComplex receptor interactionsProtein expression levelsProjection areaSerotonin 1ASerotonergic transmissionSerotonergic effectsSerotonin concentrationsSerotonergic toneRaphe regionSerotonergic neurotransmissionWhole-brain ANOVAReceptor expressionSerotonergic systemSerotonin systemGenotype statusHealthy subjectsSerotonergic structuresParahippocampal gyrus
2014
High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People
Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biological Psychiatry 2014, 78: 525-533. PMID: 25497691, PMCID: PMC4585531, DOI: 10.1016/j.biopsych.2014.09.010.Peer-Reviewed Original ResearchConceptsSerotonin reuptake transporterSERT bindingFemale transsexualsStart of treatmentSteroid hormone treatmentNew treatment modalitiesTreatment of depressionMedian raphe nucleusHormone plasma levelsTreatment-induced increaseMid-cingulate cortexPositron emission tomographyMechanism of actionTreatment startSerotonergic transmissionEstradiol levelsRaphe nucleusEstrogen treatmentReuptake transporterTreatment modalitiesAndrogen treatmentEpidemiologic findingsPlasma levelsSex hormonesSERT expression